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1. Introduction 
1.1. Classification of bone tumours 
According to World Health Organization, bone tumours can be divided into primary and 
secondary, [7]. Primitive bony tumours are classified using histo-genetic criteria and 
malignancy anatomic-clinical criteria. 
1.1.1. Tumours that form bones 
Benign: osteoma, osteoid osteoma, benign osteoblastoma; 
Malignant: osteosarcoma (osteogenic sarcoma) with subtypes: conventional, chondroblastic, 
fibroblastic, osteoblastic, telangiectatic, small cell, low-grade central, secondary, parosteal, 
periosteal, high-grade surface,[8]. 
1.1.2. Tumours that form cartilage 
Benign: chondroma, osteochondroma, chondroblastoma, chondromixoid fibroma; 
Malignant: chondrosarcoma with subtypes: central, primary and secondary, peripheral, 
dedifferentiated, mesenchymal, clear cell; 
a. Medullar tumours: Ewing sarcoma/ primitive neuroectodermal tumour;   
It is the third most common bone cancer. Most Ewing tumors start in bones, but they 
can start in other tissues and organs. This cancer is most common in children and 
teenagers. It is rare in adults over age 30. 
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b. Giant cell tumours, malignant giant cell tumours, osteoclastoma; 
c. Fibrogenic tumours: fibrosarcoma; 
d. Fibrohistiocystic tumours: malignant fibrous histiocytoma; 
e. Haematopoietic tumours: plasma cell myeloma, malignant lymphoma; 
f. Notochordal tumours: chordoma; 
g. Vascular tumours: angiosarcoma; 
h. Smooth muscle tumours: leiomyosarcoma; 
i. Lipogenic tumours: liposarcoma; 
j. Miscellaneous tumours: adamantinoma; 
 
Tumour type  Age Location Histologic aspect
Osteoma  41-50 Skull  bones Matured lamellar bone 
Osteoid osteoma 11-20 Short and long 
bones diaphysis  
Osteiod outlined by osteoblasts, 
incorporated in a fibrous stroma  
Osteosarcoma  10-25 Long bones 
metaphysis 
Osteoid and bone formed of 
malignant osteoblasts and 
fibroblasts.
Chondroma  11-40 Feet, hands Maturated hyaline cartilage 
(enchondroma/ecchondroma), 
preserving lobulation 
Chondrosarcoma 30-60 Long bones 
metaphysic, 
axial skeleton 
Immature cartilage, no 
preserving lobulation,  cells 
arranged in groups of two or 
four, with atypia and mitosis   
Ewing sarcoma 5-25 Long bones 
diaphysis 
Small, round, undifferentiated 
cells, no stroma, a lot of capillary 
arrangement. 
Giant cells tumour 20-40 Knee Multinucleated giant cells, 
fusiform cells, mononuclear 
cells. 
Metastases  50-90 Anywhere Frequently adenocarcinomas 
Table 1. Overview on tumours 
Our study revealed 198 cases of benign tumours , with a male/female ratio=1.2/1, with an 
average age of 41 years, ages between 15-78. The most afected were 21-30 and 51-60 age 
groups. A male predominance in males in 21-30 group was revealed. In 11-40 age group 
were highlighted 69 out of 108 cases (63.88%). In 51-60 age group was a female 
predominance, 27 cases. The most frequent osseous benign tumour in our study was 
osseous cyst followed by giant cell tumour(Table 1). 
In 2009-2011 in our clinic we treated 87 tumour osseous cases. Out of these, 19 were treated 
using surgical biopsy and 68 were entirely excised. Sites, morphological types of the bone 
tumours stated during the histopathological examination and their frequency are shown in 
Tables 2, 3. 
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Anatomical site Number of cases 
Hip bone 6
Proximal extremity of femur 8
Distal extremity of femur 13
Fibula 3
Proximal extremity of tibia 8
Middle 1/3 of tibia 7
Distal 1/3 of tibia 3
Synovial cyst of the leg (synovialoma) 9
Superior surface of the foot 4
Radiocarpal cyst 18
Humerus 5
Proximal 1/3 ulna 3
Table 2. Anatomical sites of the bone tumours 
 







Giant cell tumour 8
Solitary osseous mieloma 2
Table 3. Histopathological examination 
1.2. Benign tumours 
1.2.1. Solitary osseous cyst 
From microscopically point of view, is a dense osseous tissue which outlines a well -blood 
supplied connective tissue, sometimes macrophages filled with hemosiderin and colesterol.  
1.2.2. Giant cell tumour or mieloplaxe tumour or osteoclastoma 
Is composed of mononucleated stroma, with fusiform cells, well- blood supplied, and of 
giant multinucleated cells, resembling osteoclasts. Microscopically cells are multinucleated, 
giant, having a mesenchymal origin, with dimensions  10-50 microns, with 20-30 nuclei 
central situated, in a basophile cytoplasm and a fibrous stroma. 
1.2.3. Osteoid osteoma 
Is a solitary benign tumour which produces dense osseous tissue with a particular entity, 
nidus. Microscopically, the central zone contains osteoid tissue with osteoblasts, osteoclasts 
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and fibroblasts, in a network of well -blood supplied  osteoid travee. These are anastomosed 
each other and have a progressive calcification, making a final image of osteosclerosis.  
1.2.4. Osteoma 
Is a unique or multiple benign tumour, formed by bones osteoforming proliferation with 
membranous origin. Microscopically is slighty different from adult osseous tissue. It has 
irregular osseous travee, located around the haversian spaces.  
On 198 cases of benign tumours discovered and treated in Romania, we had the following 
distribution: solitary osseous cyst 66 cases, giant cell tumour 63 cases, osteoid osteoma 36 
cases, osteoma 33 cases.  
1.3. Malignant tumours  
1.3.1. Osseous metastases incidence 
In Sweden, in 10 years from a group of 832 cases of malignant primary bone  tumours 242 
were osteogenic sarcoma (28.8%), 193 chondrosarcoma (22.9%) and 74 cases Ewing’s 
sarcoma (8.8%). All three tumours showed a predilection for males,[9]. 
In Ethiopia in 2003-2008 were treated 216 bone tumour patients with a male/female ratio=1. Of 
these, 36% (74/205) were malignant. The commonest was osteosarcoma, 52/182, 28.5%, [10]. 
According to Marugame et al,[11], the distribution of histological type for primary bone 
cancer in Japanese populationfor 1993–2001 was: osteosarcoma, the most 
frequenthistological type, accounting for approximately 40%. Chondrosarcoma was the 
second-most frequent, accounting for approximately 25%. Ewing sarcoma was the third-
most frequent, accounting for approximately 10%. Malignant fibrous histocytoma and giant 
cell tumor accounted for approximately 6and 2%, respectively.  
In North America and Europe, the incidence rate for bone sarcomas in males is 
approximately 0.8 new cases/100,000 populations. Higher incidence rates have been observed 
on males in Argentina and Brazil (1.5-2/1=M/F) and Israel (1.4/1=M/F). From histological point 
of view osteosarcoma is the most common primary malignant tumour of bone, accounting for 
approximately 35%, chondrosarcoma (25%), Ewing sarcoma (16%) ,[12]. 
The most frequent cancers that give osseous metastases are: breast carcinoma, small cell 
pulmonary carcinoma, renal carcinoma, thyroid carcinoma, prostate carcinoma.  
Once the tumour metastases in the bone it becomes incurable. 20% of patients suffering from 
breast cancer live 5 years after discovering a bony metastasis. Breast and prostate cancers 
spread especially in bones.  
Osteosarcoma is the most frequent malignant primary bone tumour, with a higher incidence 
in 15-20 year old group. Male/female ratio is 1.4-1.5-1. Ewing sarcoma is the second most 
common primary malignant bone cancer, seen most frequently on children and adolescents. 
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Chondrosarcoma occurs mostly in adulthood, with a male/female ratio=1. Our data showed 
an increased percentage in males in Romania, but a 3/1 female/male ratio in Timisoara,[13]. 
1.3.2. Osteosarcoma  
Site and incidence 
Osteosarcoma is the most common primary malignant tumour of bone, more common in 
males. The incidence is 3/1,000,000 population. It accounts for <1% of all malignant 
neoplasm. The most frequent site is the distal femur, followed by the proximal tibia and the 
proximal humerus. 
In Romania field 2005-2010 were treated 468 cases of osteosarcomas with a male/female 
ratio=1.3/1, with some variability in clinics (in our clinic 7 out of 18 cases were osteosarcomas. 
Ratio F/M=3/1.) Out of these 468, 198 were benign (42.30%) and 189 malignant (40.38%). Out of 
these malignant, with a male/female ratio =1.2/1, 168 were malignant (88.88%). As benign 
tumours on the first place was osseous cyst and secondary the giant cell tumour. As age 
groups, 21-30 and 51-60 years were equal, 45 case each, with a significant difference: in the first 
group 27 cases were females and in the last one 27 cases were males. 
From primary malignant tumours point of view a ratio male/female=1.33/1. Most of these 
tumours after the histopathological examination were osteosarcomas. 
From secondary malignant tumours point of view a ratio male/female=1/1. 51 were 
carcinomas, 42 malignant fibrous histiocytomas, and 27 fibrosarcomas. 
Locations of osteosarcomas are: osseous, central, surface, gnathic, multifocal, soft tissue, 
intramuscular. 
The most frequent location was femur (50%), followed by tibia 19.6%, humerus 15.2% and 
distal fibula 2.2%.  
Accidentally, osteosarcomas could be found in hyoid bone or nasal septum.  
Histology - Microscopically types 
 Central: high-grade, conventional, telangiectatic, small cell, epitheloid, osteoblastoma-
like, chondroblastoma-like, fibrohistiocystic, giant cell; 
 Low-grade: low-grade central, fibrous dysplasia-like, desmoplastic fibroma-like; 
Surface: low-grade, parosteal, intermediate-grade, periosteal, high-grade, 
dedifferentiated parosteal, high-grade surface; 
 Intracortical; 
 Gnathic; 
 Extraskeletal: high-grade, low-grade; 
Diferent types 
 Conventional Osteosarcoma is also divided into osteoblastic, chondroblastic and 
fibroblastic subtypes according to histological feature, even from treatment and 
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response point of view there is no difference between them. Grading the osteosarcoma 
is important from oncologic point of view, because based on this could be found the 
best treatment, especially the type of surgery.  
Using Broders schema, the grade of tumour is numbered from 1 to 4, depending on the 
percentage of anaplasia, the cytologic atypia of the cells being the most important factor 
in grading tumours (Figure 1).  
 Telangiectatic Osteosarcoma is an osteosarcoma in which take place local destructions 
with replacement of anatomic spaces. New formed aneurismal bone cyst and 
production of osteoid bone can establish diagnosis.  
 Giant cell-richosteosarcomas contain osteoclast-like giant cells.  
 Small cell osteosarcoma represents a rare histological combination of osteosarcoma and 
Ewing sarcoma, until 2% of osteosarcomas.  
 Epithelioid osteosarcoma has the cell tumour poorly differentiated, for this reason 
being difficult to distinguish if is a sarcoma or a carcinoma.  
 Osteoblastoma-like and chondroblastoma-like osteosarcoma resembles osteoblastoma 
with atypical osteoblasts and having different histological feature. These tumours are 
extremely rare, but are important to be established a precise diagnosis; these could 
metastasize (Figure 2). 
 Giant cell-rich osteosarcoma contains benign multinucleated giant cells, but sometimes 
could contain lot of benign giant cells that cover the real malignant elements (Figure 3). 
 Gnathic osteosarcomas appear in maxilla and mandible bone. They are chondroblastic, 
osteoblastic, fibroblastic, small cell type concerning the matrix production.  
 Low-grade central osteosarcomas have been reported as very rarely, resembling the 
low-grade parosteal sarcoma, fibrous dysplasia and other benign lesions (Figure 4). 
 Surface osteosarcomas consist of osteosarcoma whose epicentres are out of the cortex 
of the bone outlines. According to some criteria (anatomic location, predominant 
pattern of matrix, histological grade) there are several types of surface osteosarcomas: 
parosteal osteosarcoma, periosteal osteosarcoma, dedifferentiated parosteal 
osteosarcoma, high-grade surface osteosarcoma.  
i. Parostealosteosarcoma is the most common form of surface osteosarcomas, frequently 
been confused with osteochondroma and osteoma. Is credited with < 0.5% of 
osteosarcomas, 70-83% out of them are located on distal posterior femur.  
ii. Periosteal osteosarcoma is rarely than parosteal osteosarcoma and has a cartilaginous 
matrix component. As histological grade is between I grade parosteal osteosarcoma and 
III/IV grade osteosarcoma.  
iii. Dedifferentiated parosteal osteosarcoma is composed of low-grade parosteal 
osteosarcoma and high-grade conventional parosteal osteosarcoma. According to 
Rizzoli Institute, dedifferentiation occurs in 25% of low-grade parosteal osteosarcomas. 
iv. High-grade surface osteosarcoma is microscopically high-grade. It could be possible to 
have a high-grade surface osteosarcoma that is a dedifferentiated parosteal osteosarcoma 
in which the high-grade component has replaced the low-grade component.  
 Intracortical osteosarcoma is very rare high-grade osteosarcoma that from histological 
point of view is osteoid or maybe bone formation. It is treated like conventional 
osteosarcoma (Figures 5,6). 
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 Multifocal osteosarcoma is unusual, affect children, young adults. It is a high-grade 
sarcoma, very aggressive, without escape in terms of surviving. 
 Extraskeletal osteosarcoma is credited with <2.2% of all soft tissue sarcomas. From 
histological point of view it resembles all types of osteosarcoma, even it has grown as 
soft tissue in low-grade central osteosarcoma. ¾ of patients are dying in the first 5 years 
of diagnosis. 
 
Figure 1. Conventional osteosarcoma with abundance of hyper chromatic nuclei, polyhedral tumour 
cells, sarcomatous vessels; HE staining X 100 (microscopic aspect) 
 
Figure 2. Chondroblastic osteosarcoma - compact groups of malignant tumour cells, areas with cellular 
hyaline cartilage and osteiod formation; HE staining X 100 (microscopic aspect) 
 
Figure 3. Classic osteosarcoma with an abundant production of tumour osteoid areas and bone matrix, 
enclosing giant malignant tumour cells; HE staining X400 (microscopic aspect) 
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Figure 4. Osteoid osteosarcoma- polyhedral tumour cells, with atypical mitosis, little bone and osteoid 
matrix; HE staining X 200 (microscopic aspect) 
 
Figure 5. Osteosarcoma-tumour cells having sizes and shapes variable with hyper chromatic nuclei and 
mitosis areas; HE staining X 100 (microscopic aspect) 
 
Figure 6. Osteosarcoma- polymorph tumour cells having a big size nucleus, prominent nucleolus and 
osseous matrix; HE staining X 200 (microscopic aspect) 
1.3.3. Staging bone tumours 
As Enneking et al have stated,[14], there is a system for staging bone sarcomas, according to 
correlation of the tumour location and metastases presence(Table 4);T1 - the tumour is intra 
compartmental; T2 - the tumour is extra compartmental; M0 - no regional or distant 
metastasis; M1 - regional or distant metastasis; G1 - low grade; G2 - high grade. 
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Stage Tumour Metastases Grade 
I A T1 M0 G1 
I B T2 M0 G1 
II A T1 M0 G2 
II B T2 M0 G2 
III T1 or T2 M1 G1 or G2 
Table 4. Enneking staging system for primary malignant tumours of bone 
According to American Joint Committee on Cancer Staging System [15,16] it has been used  
a new, more complex classification of the primary malignant osseous tumours, where also is 
taken into consideration the lymphatic nodes existence (Table 5), a criterion  which states the 
following:Tx - primary tumour cannot be assessed; T0 - no evidence of primary tumour; T1 - 
tumour 8 cm or less in greatest dimension; T2 - tumour more than 8 cm in greatest 
dimension; T3 - discontinuous tumours in the primary bone; Nx - regional lymph nodes not 
assessed; N0 - no regional lymph node metastases; N1 - regional lymph node metastases; 
Mx - distant metastasis cannot be assessed;  M0 - no distant metastasis; M1 - distant 
metastasis; M1a - lung;  M1b -  other distant site; Gx - grade cannot be assessed; G1 - well 
differentiated (low grade); G2 - moderately differentiated (low grade); G3 - poorly 
differentiated (high grade); G4 - undifferentiated (high grade). 
 
Stage Tumour Lymph Node Metastases Grade 
IA T1 N0 M0 G1 OR G2 
IB T2 N0 M0 G1 OR G2 
IIA T1 N0 M0 G3 OR G4 
IIB T2 N0 M0 G3 OR G4 
III T3 N0 M0 ANY G 
IVA ANY T N0 M1a ANY G 
IVB ANY T N1 ANY M ANY G 
IVB ANY T ANY N M1b ANY G 
Table 5. Staging of the primary malignant osseous tumours 
1.3.4. Chondrosarcoma 
Site and incidence 
In 1994-2007 were assessed 62 cases of chondrosarcomas in Romania, with a slightly 
decreasing for the next two years.  
Out of these 62 patients 46 were males (74.2%) and 16 females (25.8%). Male/female 
ratio=2.88/1. On age groups distribution was the following: average age of all patients was 
48.8 years, 16-81. On gender groups’ distribution was the following:  average age in females 
was 59.10, 16-78; average age in males was 45.26, 16-71. On gender and age groups the 
highest frequency is on 45-56 years in males, almost 20%. 66-75 group age in females, 9.8%.  
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As example, in 2001-2007, in Russian Federation were examined 77 patients with 
chondrosarcoma . The dedifferentiated form of the tumor was confirmed in 10 (13%) cases. 
The most common place is femur, 41.9%, followed by tibia, 16.1% and humerus 9.7%. Less 
frequent chondrosarcoma is highlighted in hip bone, 16.2%, phalanges 6.5%, and 3.1% in 
calcaneus, scapula and vertebrae. From 41.9% chondrosarcomas located on the femur 53.8% 
has a distal location. On tibia and humerus the location of a chondrosarcoma is 100% proximal. 
Histology 
From histological feature point of view, chondrosarcomas are divided in following groups: 
 Well differentiated chondrosarcoma (differential diagnosis with rich-cell chondroma); 
 Clear cell chondrosarcoma (with a “broken glass” cytoplasm);  
 Myxoid chondrosarcoma – II grade (differential diagnosis with chondromyxoid 
fibroma); 
 Dediferentiated chondrosarcoma (has a different sarcomatous area);  
 Mesenchymal chondrosarcoma.  
In order to have a precise diagnosis are followed some criteria: cellular density, cellular 
atypia, mitosis, according to these being described the grade of malignancy. Radiologic 
imaging is the first that could put a screening diagnostic, followed by MRI and RMN. 
Magnetic Resonance Imaging (MRI) can be helpful in differentiating between benign and 
malignant lesions in several ways. Greater than 90% medullar involvement can be 
suggestive of chondrosarcoma, while the absence of 90% medullar involvement of non-
contiguous areas of cartilage within the bone can suggest the presence of an enchondroma.  
In addition, the timing and progression of gadolinium contrast enhancement patterns may 
help direct a clinician toward or away from a diagnosis of malignancy. Many surgeons 
consider MRI critical for surgical planning because it can illustrate the tumour extension 
involved in bone and soft tissues [17,18]. 
 
Figure 7. Large hip joint tumour on the inferior surface of the lesser trochanter of the femur (radiologic 
images) 
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Figure 8. X- ray: Hip joint tumour, with clear, obvious, inhomogeneous outline  
 
Figure 9. MRI sagittal section: shows an important tumour, 80/50/60 mm with a lot of liquid 
On macroscopic examination, chondrosarcoma is seen like a grayish-white, lobulated mass. 
It has focal calcification and muriform aspect (Figure 10). The bigger one (2/1, 5 cm) is 
decalcified. 
Histological, the tumour is stained HE. Could be found tumour fragments with lobulated 
pattern composed of cartilage matrix which supports many chondroplasts congested with 
focal loss of arranging symmetrical character and containing not a strong polymorphism 
(Figures 11, 12, 13, 14). 
It was associated blades oblong of bone compact tissue. These were deformed and 
fragmented by the invasion of tumour tissue. Histological aspects are in favour for well-
differentiated chondrosarcoma, [19-21]. 
1.4. Survival rate 
Based on the literature data for 1995-2001, the overall 5-year relative bone cancer survival 
rate was calculated 69.4%. By rase and gender groups it was: 67.5% for Caucasian men; 
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72.1% for Caucasian women; 70% for Afro-American men; 68.4% for Afro-American 
women.  
 
Figure 10. Macroscopic aspect; exophytic sarcoma, with calcified areas and haemorrhage 
 
 




Figure 12. Malignant chondrocytes, large, atypical, with large nuclei; HE staining X 40(microscopic 
aspect) 
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Figure 13. Well-differentiated chondrosarcoma consisting of nodules hyaline matrix; 
lymphoplasmocytes infiltrate; HE staining x 10 (microscopic aspect) 
 
 
Figure 14. Well-differentiated chondrosarcoma consisting of nodules hyaline matrix; 
lymphoplasmocytes infiltrate; HE staining X 40 (microscopic aspect) 
1.5. Bone cancer statistics on stages 
This is very important for the prognosis.  
 41% of bone cancer cases are diagnosed while the cancer is still confined to the primary 
site, so it is a localized stage. 
 36% of bone cancers are diagnosed after the cancer has spread to regional lymph nodes 
or directly beyond the primary site. 
 15% of bone cancer cases are diagnosed after the cancer has already metastasizes, so it is 
a distant stage. 
 8% of bone cancer cases had staging unknown.  
 In literature cases the corresponding 5-year relative bone cancer survival rates were: 
 84.5% for localized stage; 69.4% for regional stage; 30.6% for distant stage; 62.2% for 
unknown stage. 
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2. Conclusions 
The most important thing in dealing with a bone tumour is a correct and full diagnosis. This 
include: clinical staging, a right excision, with 5 cm limits around tumour, a very precise 
histopathological examination and, not for the last, a post surgery treatment (radiotherapy, 
hormonal therapy, immunotherapy, chemotherapy). All these have in common an increase 
of 5-year survival rate. 
Taking into account that malignant primary bone tumours are few, the secondary ones, 
meaning the metastases, are the dangerous. So, besides the treating of the metastases, is also 
essential to treat, and sometimes to find, the primary tumour. It is very true that the 
secondary tumour is discovered when the primary is in an advanced stage and the rate 
survival decreases very much. 
Metastases behaviour is different from the primary tumour behaviour. Histopathological 
feature is different on breast tumours successive metastases, suggesting molecular changes 
depending on the tissue where the tumour is growing. Tumour cells preserve the initial 
pattern of the origin tissue, but the malignant phenotype is modified, depending on the 
metastazing area,[22]. 
Conventional radiography is very useful for diagnostic information. Magnetic resonance 
imaging (MRI) is recommended over computed tomography (CT) scanning for delineation 
of tumour extent before surgery. 
Nuclear imaging is limited in providing diagnosis for bony lesions. Angiography is useful 
when a compression on the vessels is suspected. Of course, is also important the location of 
the tumour on the bone. 
Histopathological examination of the biopsy sample provides with certainty the type of the 
tumour, but in some cases the tumour feature so resembles to others that is very difficult, 
even for an old specialist, to put without any doubt, a correct diagnosis. 
A longer survival of cancer patients leads to a higher risk of population to develop bone 
metastases and pathological fractures. For this reason, reconstructive procedure requires a 
guarantee longer term, in order to avoid mechanical problems during the life of the 
patient,[23]. The follow-up of the patients is multidisciplinary, including oncology, 
orthopaedics, radiology, geriatrics, endocrinology, intensive care, physiokinetotherapy. 
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